Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324162783> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2324162783 endingPage "205" @default.
- W2324162783 startingPage "200" @default.
- W2324162783 abstract "In metastatic colorectal cancer (mCRC) with wild-type K-ras, cetuximab-based regimen is an option for third-line therapy. The objective of this study was to assess if early response evaluation by 18F-FDG PET/CT can predict progression-free survival (PFS) and overall survival (OS) in these patients.Patients with mCRC going to receive third-line cetuximab-based therapy were enrolled. 18F-FDG PET/CT studies were arranged at baseline and at the ends of the first and fourth weeks of therapy. Treatment response was evaluated with 2 methods: method 1 based on PET response criteria in solid tumors 1.0 and method 2 based on the assumption that an increase in peak tumor metabolism implies nonresponse. Progression-free survival was counted to tumor progression based on the Response Evaluation Criteria in Solid Tumors 1.1 or death. The predictive powers for PFS and OS were analyzed using the Kaplan-Meier method and the log-rank test.Twenty-seven patients were eligible with a median PFS of 5.8 months and a median OS of 9.1 months. Method 2 predicts PFS (P = 0.001) and OS (P < 0.001) at the end of the first week, whereas method 1 does not. Both methods predict PFS and OS at the end of the fourth week.Early response evaluation by 18F-FDG PET/CT predicts PFS and OS in patients with mCRC receiving third-line cetuximab-based therapy. Early therapeutic change may be possible for nonresponsive patients after 1 week of treatment." @default.
- W2324162783 created "2016-06-24" @default.
- W2324162783 creator A5041593760 @default.
- W2324162783 creator A5047575413 @default.
- W2324162783 creator A5047749147 @default.
- W2324162783 creator A5068912777 @default.
- W2324162783 date "2015-03-01" @default.
- W2324162783 modified "2023-10-01" @default.
- W2324162783 title "Early Prediction by 18F-FDG PET/CT for Progression-Free Survival and Overall Survival in Patients With Metastatic Colorectal Cancer Receiving Third-Line Cetuximab-Based Therapy" @default.
- W2324162783 cites W1585383225 @default.
- W2324162783 cites W1772207639 @default.
- W2324162783 cites W1995308403 @default.
- W2324162783 cites W2032157317 @default.
- W2324162783 cites W2072248738 @default.
- W2324162783 cites W2074195384 @default.
- W2324162783 cites W2084693381 @default.
- W2324162783 cites W2100276373 @default.
- W2324162783 cites W2100543432 @default.
- W2324162783 cites W2108549165 @default.
- W2324162783 cites W2109509934 @default.
- W2324162783 cites W2109996356 @default.
- W2324162783 cites W2113720689 @default.
- W2324162783 cites W2123534406 @default.
- W2324162783 cites W2133399075 @default.
- W2324162783 cites W2142564546 @default.
- W2324162783 cites W2150540531 @default.
- W2324162783 cites W2155263737 @default.
- W2324162783 cites W2155311724 @default.
- W2324162783 cites W2156700619 @default.
- W2324162783 cites W2225412566 @default.
- W2324162783 doi "https://doi.org/10.1097/rlu.0000000000000693" @default.
- W2324162783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25608159" @default.
- W2324162783 hasPublicationYear "2015" @default.
- W2324162783 type Work @default.
- W2324162783 sameAs 2324162783 @default.
- W2324162783 citedByCount "24" @default.
- W2324162783 countsByYear W23241627832015 @default.
- W2324162783 countsByYear W23241627832016 @default.
- W2324162783 countsByYear W23241627832017 @default.
- W2324162783 countsByYear W23241627832018 @default.
- W2324162783 countsByYear W23241627832019 @default.
- W2324162783 countsByYear W23241627832020 @default.
- W2324162783 countsByYear W23241627832021 @default.
- W2324162783 countsByYear W23241627832022 @default.
- W2324162783 countsByYear W23241627832023 @default.
- W2324162783 crossrefType "journal-article" @default.
- W2324162783 hasAuthorship W2324162783A5041593760 @default.
- W2324162783 hasAuthorship W2324162783A5047575413 @default.
- W2324162783 hasAuthorship W2324162783A5047749147 @default.
- W2324162783 hasAuthorship W2324162783A5068912777 @default.
- W2324162783 hasConcept C121608353 @default.
- W2324162783 hasConcept C126322002 @default.
- W2324162783 hasConcept C143998085 @default.
- W2324162783 hasConcept C2779998722 @default.
- W2324162783 hasConcept C2780739268 @default.
- W2324162783 hasConcept C2781413609 @default.
- W2324162783 hasConcept C3019894029 @default.
- W2324162783 hasConcept C526805850 @default.
- W2324162783 hasConcept C71924100 @default.
- W2324162783 hasConceptScore W2324162783C121608353 @default.
- W2324162783 hasConceptScore W2324162783C126322002 @default.
- W2324162783 hasConceptScore W2324162783C143998085 @default.
- W2324162783 hasConceptScore W2324162783C2779998722 @default.
- W2324162783 hasConceptScore W2324162783C2780739268 @default.
- W2324162783 hasConceptScore W2324162783C2781413609 @default.
- W2324162783 hasConceptScore W2324162783C3019894029 @default.
- W2324162783 hasConceptScore W2324162783C526805850 @default.
- W2324162783 hasConceptScore W2324162783C71924100 @default.
- W2324162783 hasIssue "3" @default.
- W2324162783 hasLocation W23241627831 @default.
- W2324162783 hasLocation W23241627832 @default.
- W2324162783 hasOpenAccess W2324162783 @default.
- W2324162783 hasPrimaryLocation W23241627831 @default.
- W2324162783 hasRelatedWork W1908989187 @default.
- W2324162783 hasRelatedWork W2049754458 @default.
- W2324162783 hasRelatedWork W2280217121 @default.
- W2324162783 hasRelatedWork W2325657449 @default.
- W2324162783 hasRelatedWork W2435704186 @default.
- W2324162783 hasRelatedWork W2439403919 @default.
- W2324162783 hasRelatedWork W2598512998 @default.
- W2324162783 hasRelatedWork W3026015583 @default.
- W2324162783 hasRelatedWork W4237412880 @default.
- W2324162783 hasRelatedWork W4292087709 @default.
- W2324162783 hasVolume "40" @default.
- W2324162783 isParatext "false" @default.
- W2324162783 isRetracted "false" @default.
- W2324162783 magId "2324162783" @default.
- W2324162783 workType "article" @default.